Amy K Wagner1. 1. Department of Physical Medicine and Rehabilitation, University of Pittsburgh, 3471 Fifth Avenue Suite 202, Kaufman Building, Pittsburgh, PA, 15213, USA. wagnerak@upmc.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to summarize how "-omics" technologies can inform rehabilitation-relevant outcomes for a range of populations with neurologically related disability by including outcome metrics linked to the World Health Organization's International Classification of Functioning, Disability, and Health (WHO-ICF) domains of impairments in body function, activity limitations, and participation restrictions. RECENT FINDINGS: To date, nearly every area of medicine uses biomarkers in some capacity to aid in understanding how personal biology informs clinical care. "-Omics"-based approaches use high throughput genomics, proteomics, and transcriptomics assay platforms to tailor and personalize treatments for subgroups of similar individuals based on these results. The recent Precision Medicine Initiative (PMI), sponsored by the National Institutes of Health (NIH), has propelled biomarker-based and genomics research to the forefront of many translational research and care programs addressing a variety of medical populations. Yet, the literature is sparse on precision medicine approaches for those with neurologically related and other disability. We demonstrate how the Rehabilomics Research model represents a translational framework for programs of precision rehabilitation research and care focused on linking personal biology to the biopsychosocial constructs that represent the WHO-ICF model and multidimensional outcome. We provide multiple exemplars from our own research program involving individuals with moderate-to-severe traumatic brain injury (TBI) to demonstrate how genomics and other biomarkers can be identified and assessed for their capacity to assist with personalized (precision) neurorehabilitation care and management.
PURPOSE OF REVIEW: The purpose of this review is to summarize how "-omics" technologies can inform rehabilitation-relevant outcomes for a range of populations with neurologically related disability by including outcome metrics linked to the World Health Organization's International Classification of Functioning, Disability, and Health (WHO-ICF) domains of impairments in body function, activity limitations, and participation restrictions. RECENT FINDINGS: To date, nearly every area of medicine uses biomarkers in some capacity to aid in understanding how personal biology informs clinical care. "-Omics"-based approaches use high throughput genomics, proteomics, and transcriptomics assay platforms to tailor and personalize treatments for subgroups of similar individuals based on these results. The recent Precision Medicine Initiative (PMI), sponsored by the National Institutes of Health (NIH), has propelled biomarker-based and genomics research to the forefront of many translational research and care programs addressing a variety of medical populations. Yet, the literature is sparse on precision medicine approaches for those with neurologically related and other disability. We demonstrate how the Rehabilomics Research model represents a translational framework for programs of precision rehabilitation research and care focused on linking personal biology to the biopsychosocial constructs that represent the WHO-ICF model and multidimensional outcome. We provide multiple exemplars from our own research program involving individuals with moderate-to-severe traumatic brain injury (TBI) to demonstrate how genomics and other biomarkers can be identified and assessed for their capacity to assist with personalized (precision) neurorehabilitation care and management.
Entities:
Keywords:
Disability; Function; Precision medicine; Rehabilomics; Traumatic brain injury; World Health Organization International Classification of Functioning Disability and Health (WHO-ICF)
Authors: Michelle D Failla; John M Myrga; Joseph H Ricker; C Edward Dixon; Yvette P Conley; Amy K Wagner Journal: J Head Trauma Rehabil Date: 2015 Nov-Dec Impact factor: 2.710
Authors: John K Yue; Angela M Pronger; Adam R Ferguson; Nancy R Temkin; Sourabh Sharma; Jonathan Rosand; Marco D Sorani; Thomas W McAllister; Jason Barber; Ethan A Winkler; Esteban G Burchard; Donglei Hu; Hester F Lingsma; Shelly R Cooper; Ava M Puccio; David O Okonkwo; Ramon Diaz-Arrastia; Geoffrey T Manley Journal: Neurogenetics Date: 2015-01-30 Impact factor: 2.660
Authors: John M Myrga; Shannon B Juengst; Michelle D Failla; Yvette P Conley; Patricia M Arenth; Anthony A Grace; Amy K Wagner Journal: Neurorehabil Neural Repair Date: 2016-05-06 Impact factor: 3.919
Authors: Shannon Juengst; Elizabeth Skidmore; Patricia M Arenth; Christian Niyonkuru; Ketki D Raina Journal: Arch Phys Med Rehabil Date: 2012-08-09 Impact factor: 3.966
Authors: Steven M Markos; Michelle D Failla; Anne C Ritter; C Edward Dixon; Yvette P Conley; Joseph H Ricker; Patricia M Arenth; Shannon B Juengst; Amy K Wagner Journal: J Head Trauma Rehabil Date: 2017 Mar/Apr Impact factor: 2.710
Authors: Patrick M Kochanek; Travis C Jackson; Ruchira M Jha; Robert S B Clark; David O Okonkwo; Hülya Bayır; Samuel M Poloyac; Amy K Wagner; Philip E Empey; Yvette P Conley; Michael J Bell; Anthony E Kline; Corina O Bondi; Dennis W Simon; Shaun W Carlson; Ava M Puccio; Christopher M Horvat; Alicia K Au; Jonathan Elmer; Amery Treble-Barna; Milos D Ikonomovic; Lori A Shutter; D Lansing Taylor; Andrew M Stern; Steven H Graham; Valerian E Kagan; Edwin K Jackson; Stephen R Wisniewski; C Edward Dixon Journal: J Neurotrauma Date: 2019-02-01 Impact factor: 5.269
Authors: Catherine Madurski; Jessica M Jarvis; Sue R Beers; Amy J Houtrow; Amy K Wagner; Anthony Fabio; Chunyan Wang; Craig M Smith; Lesley Doughty; Keri Janesko-Feldman; Pamela Rubin; Dorothy Pollon; Amery Treble-Barna; Patrick M Kochanek; Ericka L Fink Journal: Neurocrit Care Date: 2021-03-04 Impact factor: 3.532
Authors: Flora M Hammond; Sheryl Katta-Charles; Mary Beth Russell; Ross D Zafonte; Jan Claassen; Amy K Wagner; Louis Puybasset; Satoshi Egawa; Steven Laureys; Michael Diringer; Robert D Stevens Journal: Neurocrit Care Date: 2021-07-08 Impact factor: 3.532